OMER
Omeros Corporation · Healthcare · Biotechnology
Momentum-inputs (vergelijkbare managers):
breedte van houders -2.7% ·
aandelenstroom -7.3% ·
netto nieuwe posities -2.8%
· formule
Brede distributie: dalende aandelen en minder houders
Alle eigendomscijfers: uitsluitend gevolgde 13F-managers, posities in gewone aandelen, rapportageperiode Q4 2025
| Kwartaal | Houders | Δ | Aandelen | Gerapporteerde waarde | Nieuw | Uitstappen |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | +1 | 30.11K | $575,627 | +1 | −1 |
| Q2 2026 | 74 | -1 | 26.77M | $254.67M | +8 | −10 |
| Q1 2026 | 78 | +7 | 23.56M | $249.21M | +9 | −2 |
| Q4 2025 | 71 | -2 | 30.19M | $466.97M | n/a | −2 |
| Q3 2025 | 17 | 0 | 17.59M | $72.13M | n/a | n/a |
| Q2 2025 | 14 | +1 | 14.04M | $42.12M | +1 | n/a |
| Q1 2025 | 10 | +1 | 6.15M | $50.54M | +1 | n/a |
| Q4 2024 | 9 | 0 | 4.83M | $47.77M | +1 | −1 |
| Q3 2024 | 8 | +1 | 3.34M | $13.26M | +1 | n/a |
| Q2 2024 | 7 | n/a | 3.21M | $13.02M | n/a | n/a |
| # | Manager | Aandelen | Δ aandelen | Waarde | Hun gewicht | Gehouden | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (passief) | 4.01M | +19.9% | $68.93M | 0.0% | ▲ Add | 3 | SEC ↗ ×3 |
| 2 | Stifel Financial Corp | 1.81M | n/a | $31.08M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 3 | State Street Global Advisors ✦ (passief) | 1.57M | +26.9% | $27.03M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 4 | Charles Schwab Investment… | 593.22K | n/a | $10.19M | 0.0% | n/c | 1 | SEC ↗ |
| 5 | Northern Trust Corp | 526.73K | n/a | $9.05M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 6 | Goldman Sachs Group ✦ | 227.29K | -32.4% | $3.90M | 0.0% | ▼ Trim | 2 | SEC ↗ ×2 |
| 7 | Wells Fargo & Company/Mn | 165.28K | n/a | $2.84M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 8 | Barclays Plc | 120.49K | n/a | $2.07M | 0.0% | n/c | 1 | SEC ↗ |
| 9 | Ameriprise Financial Inc | 117.00K | n/a | $2.01M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 10 | Bank Of America Corp /De/ | 114.81K | n/a | $1.97M | 0.0% | n/c | 1 | SEC ↗ ×6 |
| 11 | Dimensional Fund Advisors Lp | 96.95K | n/a | $1.67M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 12 | T. Rowe Price ✦ | 95.75K | +6.9% | $1.64M | 0.0% | ▲ Add | 7 | SEC ↗ |
| 13 | Mml Investors Services, Llc | 77.88K | n/a | $1.34M | 0.0% | n/c | 1 | SEC ↗ |
| 14 | JPMorgan Chase ✦ | 37.19K | -95.5% | $638,755 | 0.0% | ▼ Trim | 2 | SEC ↗ ×4 |
| 15 | Sei Investments Co | 31.77K | n/a | $545,577 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 16 | Citigroup Inc | 27.49K | n/a | $472,124 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 17 | New York State Common Retirement… | 20.71K | n/a | $355,746 | 0.0% | n/c | 1 | SEC ↗ |
| 18 | Fidelity (FMR) ✦ | 18.07K | +37.0% | $310,325 | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 19 | Raymond James Financial Inc | 12.24K | n/a | $210,256 | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 20 | Legal & General Group Plc | 6.97K | n/a | $119,727 | 0.0% | n/c | 1 | SEC ↗ |
| 21 | Fifth Third Bancorp | 1.00K | n/a | $17,175 | 0.0% | n/c | 1 | SEC ↗ |
| 22 | Pnc Financial Services Group, Inc. | 377 | n/a | $6,475 | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 23 | UBS AM, a distinct business unit of… | 231 | n/a | $3,967 | 0.0% | n/c | 1 | SEC ↗ |
"Hun weging" = het aandeel van de positie in de gerapporteerde 13F-aandelenwaarde van die manager: de overtuigingsmaatstaf. ✦ = gecureerde manager.
Nieuwe kopers
| Geen nieuwe bijgehouden kopers dit kwartaal. |
Verlaten
| Geen bijgehouden uitstappen dit kwartaal. |
Volledige marktcontext: over ALLE 13F-indieners (SEC gestructureerde data, Q1 2026): 1 houders, 4.17M aandelen, $8.90M gerapporteerd. Dit betreft een andere, oudere periode dan de bovenstaande cijfers van het gevolgde universum; beide worden nooit gecombineerd.
Wat de gevolgde houders van dit effect het vaakst nog meer bezitten: aantallen gedeeld eigendom, geen fundamentele relaties.
Open-market aankopen (P)
Geen open-market insider-aankopen in ons dekkingsvenster.
Open-market verkopen (S)
Officer · 10.00K aand · $209,500
Officer · 10.00K aand · $209,500
Officer · 25.00K aand · $463,540
Officer · 25.00K aand · $466,128
Director · 5.00K aand · $94,381
Director · 5.00K aand · $95,080
Director · 5.00K aand · $92,632
Officer · 906 aand · $17,305
Officer · 10.00K aand · $189,500
Director · 15.00K aand · $276,772
Toekenningen, uitoefeningen en belastinginhoudingen worden hier nooit meegeteld als aankopen of verkopen. Methodologie